Latest Stock Advice
Activist investors are circling: uncover dividend-paying companies with resilient payouts and strong fundamentals from TSI’s latest Globe and Mail feature.
Nutrien Ltd. offers exposure to potash and nitrogen prices, a stable retail base and strong profitability.
Groupe Dynamite Inc. is a high‑quality specialty retailer with gains ahead.
Teck Resources Ltd. is a solid bet on higher copper prices with its big merger winning approvals
Become a Successful Investor
When investing in rare earth metals, you need to look at the unique geographical and political environment the mining company produces in.
There will always be stocks you’ll wish you bought, especially after you see their growth. Here’s what to look for so you won’t miss out.
On July 1, 2015, Baxter International handed out 80.5% the shares in its Baxalta subsidiary to its investors on a one-for-one basis. Baxalta makes vaccines and drugs in three main areas: hematology (blood diseases), immunology (immune system) and oncology (cancer). Baxter now focuses on medical devices, such as intravenous pumps and kidney-dialysis equipment, and operating room drugs such as anesthesia. BAXTER INTERNATIONAL INC. $39 (New York symbol BAX; Conservative Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 547.0 million; Market cap: $21.3 billion; Price-to-sales ratio: 2.1; Dividend yield: 1.2%; TSINetwork Rating: Average; www.baxter.com) earned $755 million, or $1.38 a share, in 2015 before unusual items. That’s up 7.5% from $702 million, or $1.28, in 2014. Revenue fell 7.0%, to $10.0 billion from $10.7 billion. However, without the negative impact of currency exchange rates, revenue gained 3%....
PFIZER INC. $30(New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 6.2 billion; Market cap: $186.0 billion; Price-to-sales ratio: 3.8; Dividend yield: 4.0%; TSINetwork Rating: Above Average; www.pfizer.com) acquired rival drug maker Wyeth in October 2009. Wyeth has now agreed to pay the U.S. Medicaid system $784.6 million to settle a dispute over how it calculated rebates for its Protonix acid reflux drug between 2001 and 2006. Pfizer will have to restate its earnings for 2015 to reflect this charge. However, its earnings before unusual items of $2.20 a share remains unchanged....
C.R. BARD INC. $194 (New York symbol BCR; Conservative Growth Portfolio, Consumer sector; Shares outstanding: 73.7 million; Market cap: $14.3 billion; Price-to-sales ratio: 4.2; Dividend yield: 0.5%; TSINetwork Rating: Above Average; www.crbard.com) has acquired Liberator Medical Holdings for $181 million. This firm distributes a variety of medical products such as urological catheters and diabetic supplies, directly to consumers’homes. Under the deal, Bard plans to expand the availability of its own medical devices. That should add $70 million to its annual sales of $3.4 billion, and $0.05 to $0.10 a share to its annual earnings in 2017; Bard will probably earn $9.97 a share in 2016. The stock trades at a reasonable 19.5 times that forecast. C.R. Bard is a buy....
MCCORMICK & CO. INC. $93(New York symbol MKC; Income Portfolio, Consumer sector; Shares outstanding: 115.4 million; Market cap: $10.7 billion; Price-to-sales ratio: 3.8; Dividend yield: 1.8%; TSINetwork Rating: Average; www.mccormick.com) makes spices, herbs, seasonings and flavours. The company earned $449.5 million in the fiscal year ended November 30, 2015, up 1.8% from $441.6 million in 2014. Due to fewer shares outstanding, per-share earnings rose 3.3%, to $3.48 from $3.37. Sales rose just 1.3%, to $4.3 billion from $4.2 billion. That’s a 6.4% gain when currency exchange rates are factored out. McCormick aims to save a total of $400 million over the next four years, mainly through job cuts and new, more efficient manufacturing equipment. However, the stock is expensive at 25.2 times the $3.69 a share that the company expects to earn in fiscal 2016....